hCLiP-EV

hCLiP-EV (also known as EVIA 2068) is an exosome-based therapy consisting of small extracellular vesicles (sEVs) derived from human chemically induced liver progenitor cells (hCLiPs). Developed by EVIA Life Sciences in collaboration with Keio University and Tokyo Medical University, hCLiP-EV is being investigated as a cell-free therapeutic for the treatment of liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). The therapeutic efficacy of hCLiP-EV is primarily driven by its bioactive RNA cargo, particularly microRNAs such as miR-122-5p and miR-29a-3p. In preclinical models of MASH, hCLiP-EV has been shown to attenuate hepatic fibrosis through model-dependent mechanisms, including the direct deactivation of hepatic stellate cells (HSCs), attenuation of Kupffer cell and macrophage-mediated inflammation, and selective suppression of connective tissue growth factor (CTGF/CCN2) and B-cell activation.

Other names

hCLiP-derived extracellular vesicleshCLiP-derived sEVshCLiP-sEVhCLiP-sEVshuman chemically induced liver progenitor cell-derived extracellular vesicleshuman chemically induced liver progenitor cell-derived small extracellular vesicles